Tyrosine kinase inhibitors (TKIs) targeting EGFR-mutant lung cancers promote a range of
tumor regression responses to yield variable residual disease, a likely incubator for acquired …

Oncolytic virus therapies induce the direct killing of tumor cells and activation of
conventional dendritic cells (cDC); however, cDC activation has not been optimized with …

Background Programmed death 1/programmed death ligand 1 (PD-1/PD-L1) targeted
immunotherapy affords clinical benefit in~ 20% of unselected patients with lung cancer. The …

Epigenetic regulation plays a crucial role in the development and progression of cancer,
including the regulation of antitumor immunity. The reversible nature of epigenetic …

Medulloblastoma (MB) is the most common primary malignant pediatric brain cancer. We
recently identified novel roles for the MEK/MAPK pathway in regulating human Sonic …

In this issue of Cancer Research, Xie and colleagues reveal an unexpected synergy
between MEK inhibitors and immune checkpoint blockade in non–small cell lung cancer …

Lung cancer is the leading cause of cancer deaths worldwide. The tumorigenesis of KRAS-
mutated lung adenocarcinoma (LUAD) is associated with an inflammatory process …

Oncogenic mutations that occur in the receptor tyrosine kinases (RTKs) such as EGFR and
ALK are present in a significant subset of lung cancer patients, most which present with …

Disclosed are and methods for expanding tumor infiltrating lymphocyte (TIL) populations
and methods of the use of the expanded TIL population for treating cancer. In one aspect …